Pier Capital LLC Boosts Stock Position in Capricor Therapeutics, Inc. $CAPR

Pier Capital LLC increased its holdings in Capricor Therapeutics, Inc. (NASDAQ:CAPR) by 35.0% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 496,554 shares of the biotechnology company’s stock after purchasing an additional 128,837 shares during the period. Pier Capital LLC owned approximately 1.09% of Capricor Therapeutics worth $3,580,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. Russell Investments Group Ltd. lifted its position in Capricor Therapeutics by 122.2% during the third quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 2,786 shares during the last quarter. Legal & General Group Plc increased its holdings in shares of Capricor Therapeutics by 8.4% in the 2nd quarter. Legal & General Group Plc now owns 41,273 shares of the biotechnology company’s stock worth $410,000 after buying an additional 3,205 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of Capricor Therapeutics by 7.3% in the 2nd quarter. Rhumbline Advisers now owns 53,450 shares of the biotechnology company’s stock worth $531,000 after buying an additional 3,636 shares during the last quarter. Farther Finance Advisors LLC purchased a new stake in shares of Capricor Therapeutics during the 3rd quarter valued at about $28,000. Finally, Tower Research Capital LLC TRC raised its position in shares of Capricor Therapeutics by 280.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock valued at $67,000 after buying an additional 4,976 shares in the last quarter. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Trading Down 0.4%

CAPR stock opened at $33.42 on Friday. Capricor Therapeutics, Inc. has a 12 month low of $4.30 and a 12 month high of $40.37. The company has a 50-day moving average price of $25.66 and a 200 day moving average price of $16.35. The stock has a market cap of $1.85 billion, a PE ratio of -18.57 and a beta of 0.37.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Wednesday, March 18th. The biotechnology company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11). Sell-side analysts forecast that Capricor Therapeutics, Inc. will post -1.21 EPS for the current year.

Key Headlines Impacting Capricor Therapeutics

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: FDA resumed its review of Capricor’s BLA for Deramiocel and lifted a prior Complete Response Letter, setting a new regulatory timeline — a material positive for approval prospects and valuation. FDA reconsidering Capricor’s snubbed DMD cell therapy after ‘lifting’ rejection
• Positive Sentiment: Late-breaking HOPE-3 Phase 3 data presented at the MDA conference showed significant functional benefits of Deramiocel in Duchenne muscular dystrophy — strengthens the clinical case behind the BLA. Capricor Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference
• Positive Sentiment: Analyst support: HC Wainwright reiterated a Buy rating on CAPR, which can provide continued buy-side interest. HC Wainwright Reiterates Buy Rating for Capricor Therapeutics
• Positive Sentiment: Additional study coverage reported improvements in key heart-function measures for Capricor’s DMD treatment, reinforcing clinical momentum. Capricor Therapeutics’ DMD treatment study shows improvement in key heart function measures
• Neutral Sentiment: Capricor published its fourth-quarter and full-year 2025 financial results and a corporate update; investors will parse cash runway and expense guidance vs. clinical/regulatory milestones. Q4 and Full Year 2025 Financial Results and Corporate Update
• Neutral Sentiment: Pre-earnings/coverage pieces noted that earnings are on deck after the FDA resumed review — these previews can amplify volatility but don’t change fundamentals by themselves. Capricor earnings on deck after FDA resumes deramiocel review
• Neutral Sentiment: Reported short-interest notices show inconsistent/zero data (NaN/0 shares), indicating no reliable short-interest signal from the public filings provided. Investors should treat these short-interest items as data-noise until clarified.
• Negative Sentiment: Capricor missed quarterly EPS estimates (reported a loss of $0.62 vs. consensus -$0.51), which increases near-term earnings disappointment risk and can pressure the stock until revenue/cost outlooks are addressed. Press Release — Quarterly Earnings

Analysts Set New Price Targets

Several research analysts recently commented on the company. Oppenheimer lifted their price target on Capricor Therapeutics from $22.00 to $54.00 and gave the stock an “outperform” rating in a research report on Monday, December 8th. Piper Sandler restated an “overweight” rating and set a $45.00 price objective (up from $20.00) on shares of Capricor Therapeutics in a research report on Wednesday, December 10th. UBS Group set a $50.00 price objective on Capricor Therapeutics in a research note on Monday, December 15th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Capricor Therapeutics in a report on Wednesday, January 14th. Finally, Wall Street Zen downgraded Capricor Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, January 11th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $40.82.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.